Technical Analysis for ATNX - Athenex, Inc.

Grade Last Price % Change Price Change
grade A 13.95 0.14% 0.02
ATNX closed up 0.14 percent on Monday, May 20, 2019, on approximately normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical ATNX trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Calm After Storm Range Contraction 0.14%
Wide Bands Range Expansion 0.14%
Overbought Stochastic Strength 0.14%
Calm After Storm Range Contraction -0.92%
Wide Bands Range Expansion -0.92%
Overbought Stochastic Strength -0.92%
180 Bullish Setup Bullish Swing Setup -0.50%
Outside Day Range Expansion -0.50%

Older signals for ATNX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Athenex, Inc. is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company's technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics. The Company offers Oraxol, an oral formulation of paclitaxel; Orateacan, an oral formulation of Irinotecan; Oradoxel, an oral formulation of Docetaxel, and an oral formulation of Topotecan for the treatment of various types of cancers. Its Src Kinase Inhibitors include KX-01 (KX2-391) and KX-02 (KX2-361) oncology drug candidates. The Company's Symptom Therapeutics include CQ-01, which is used for the treatment of burn pruritus and scars; CQ-R1, which is used for the treatment of an irradiation-induced dermatitis, and an intranasal Granisetron used for the treatment of chemotherapy-induced nausea/vomiting.
Chemistry Organic Compounds Oncology Cancers Chemotherapy Organic Chemistry Antineoplastic Drugs Therapies For Cancer Pruritus Docetaxel Paclitaxel Scars Treatment Of Various Types Of Cancers
Is ATNX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 20.9
52 Week Low 9.38
Average Volume 398,726
200-Day Moving Average 13.27
50-Day Moving Average 12.0016
20-Day Moving Average 12.145
10-Day Moving Average 13.693
Average True Range 0.7042
ADX 34.92
+DI 34.693
-DI 14.9312
Chandelier Exit (Long, 3 ATRs ) 12.6374
Chandelier Exit (Short, 3 ATRs ) 11.492600000000001
Upper Bollinger Band 15.5899
Lower Bollinger Band 8.7001
Percent B (%b) 0.76
BandWidth 56.729518
MACD Line 0.7107
MACD Signal Line 0.4565
MACD Histogram 0.2543
Fundamentals Value
Market Cap 796.03 Million
Num Shares 57.1 Million
EPS -3.47
Price-to-Earnings (P/E) Ratio -4.02
Price-to-Sales 47.88
Price-to-Book 7.97
PEG Ratio 0.98
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 14.63
Resistance 3 (R3) 14.61 14.38 14.51
Resistance 2 (R2) 14.38 14.20 14.38 14.47
Resistance 1 (R1) 14.16 14.10 14.27 14.18 14.44
Pivot Point 13.93 13.93 13.98 13.93 13.93
Support 1 (S1) 13.71 13.75 13.82 13.73 13.46
Support 2 (S2) 13.48 13.65 13.48 13.43
Support 3 (S3) 13.26 13.48 13.39
Support 4 (S4) 13.28